Amedisys
AMED
AMED was delisted on the 14th of August, 2025.
281 hedge funds and large institutions have $2.32B invested in Amedisys in 2023 Q1 according to their latest regulatory filings, with 42 funds opening new positions, 106 increasing their positions, 96 reducing their positions, and 33 closing their positions.
265% more call options, than puts
Call options by funds: $6.04M | Put options by funds: $1.65M
27% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 33
10% more repeat investments, than reductions
Existing positions increased: 106 | Existing positions reduced: 96
1% more funds holding
Funds holding: 277 → 281 (+4)
0.88% more ownership
Funds ownership: 95.72% → 96.6% (+0.88%)
10% less capital invested
Capital invested by funds: $2.56B → $2.32B (-$249M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$30M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
+$24.4M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$20.6M |
| 4 |
JP Morgan Chase
New York
|
+$20.5M |
| 5 |
EP
Eversept Partners
New York
|
+$19.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$92.5M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$46.1M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
-$23.4M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$17.6M |
| 5 |
Bank of New York Mellon
New York
|
-$11.5M |
AMED Hedge Fund Activity: Q1 2023 in Review
281 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Amedisys (AMED) for Q1 2023, worth a combined $2.32B — down 9.7% from $2.56B a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new AMED positions and 33 closed out — a net gain of 9 holders — while 106 added to existing stakes and 96 trimmed.
The largest buyer was Deerfield Management, adding an estimated $30M. The largest seller was BlackRock, cutting an estimated $92.5M.
- 281 institutional investors held Amedisys (AMED) as of Q1 2023, up from 277 in Q4 2022.
- Funds reported $2.32B of Amedisys stock for Q1 2023, down 9.7% quarter-over-quarter.
- 42 funds opened new Amedisys positions in Q1 2023 and 33 closed out, a net change of +9 holders.
- The largest Amedisys buyer in Q1 2023 was Deerfield Management, an estimated $30M added.
- The largest Amedisys seller in Q1 2023 was BlackRock, an estimated $92.5M sold.
Based on aggregated 13F filings for Q1 2023.